Evidence map›Paper›PMID 40087295›Full record

ArticleScientific reports2025

YTHDC1 negatively regulates UBE3A to influence RAD51 ubiquitination and inhibit apoptosis in colorectal cancer cells.

Mingwei Gao, Yueguang Wu, Li Zhang, Yan Zhou, Huijuan Liu, Weimin Zhang, Shubin Wang, Yongping Cui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. The mMolecular biomedicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mingwei GaoCancer Institute, Shenzhen Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Yueguang WuCancer Institute, Shenzhen Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Li ZhangCancer Institute, Shenzhen Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Yan ZhouKey Laboratory of Cellular Physiology of the Ministry of Education, Department of Pathology, Shanxi Medical University, Taiyuan, Shanxi, China.
Huijuan LiuKey Laboratory of Cellular Physiology of the Ministry of Education, Department of Pathology, Shanxi Medical University, Taiyuan, Shanxi, China.
Weimin ZhangCancer Institute, Shenzhen Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Shubin WangCancer Institute, Shenzhen Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China. wangshubin2013@163.com.
Yongping CuiCancer Institute, Shenzhen Peking University-Hong Kong University of Science and Technology (PKU-HKUST) Medical Center, Shenzhen Key Laboratory of Gastrointestinal Cancer Translational Research, Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China. cuiyp@sphmc.org.

Funding

China National Postdoctoral Program for Innovative Talents BX20220214Guangdong Basic and Applied Basic Research Foundation 2019B030302012Major Program of Shenzhen Bay Laboratory S201101004National Key R&D Program of China 2021YFC2501001National Natural Science Foundation of China 82172930National Natural Science Foundation of China 82203286National Natural Science Foundation of China 82341024Shenzhen Medical Research Funds C2303002Shenzhen "San-Ming" Project of Medicine SZSM202211036Shenzhen "San-Ming" Project of Medicine SZSM202311014Shenzhen Science and Technology Innovation Commission Project ZDSYS20190902092855097
6 · The paper itself

Abstract

YTHDC1, a key protein in the m

Indexed as

ApoptosisColorectal NeoplasmsRad51 RecombinaseRNA Splicing FactorsUbiquitinationUbiquitin-Protein LigasesCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansRAD51 protein, humanRad51 RecombinaseRNA Splicing FactorsUbiquitin-Protein LigasesCell apoptosisColorectal tumorRAD51UBE3AYTHDC1

Identifiers

PMID40087295
PMCPMC11909180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.